Antibodies and genetically engineered related molecules: production and purification.
about
Gene delivery into plant cells for recombinant protein production.Biopharmaceuticals from microorganisms: from production to purificationImmunoabsorbent nanoparticles based on a tobamovirus displaying protein A.Affinity polymers tailored for the protein A binding site of immunoglobulin G proteins.Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.Conformational and aggregation properties of a PEGylated alanine-rich polypeptideProduction of human antibody fragments binding to melittin and phospholipase A2 in Africanised bee venom: minimising venom toxicity.Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D.The Structural Role of Antibody N-Glycosylation in Receptor InteractionsImmunotherapy and immunoprevention of cancer: where do we stand?Using polyclonal and monoclonal antibodies in regulatory testing of biological products.Factors of importance for a successful delivery system for proteins.Engineered synthetic polymer nanoparticles as IgG affinity ligandsPlant-derived virus-like particles as vaccinesEffects of glycosylation on the stability of protein pharmaceuticals.Norwalk virus-like particles as vaccines.Potential applications of designed ankyrin repeat proteins in diagnostics and therapeutics.Different types of aqueous two-phase systems for biomolecule and bioparticle extraction and purification.Monoclonal antibodies as therapeutics in human malignancies.Magnetic nanoparticles as potential candidates for biomedical and biological applications.Antibody Engineering for Pursuing a Healthier FutureCell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Immunoaffinity Chromatography: Concepts and Applications.Rapid transient expression of human granulocyte-macrophage colony-stimulating factor in two industrial cultivars of tobacco (Nicotiana tabacum L.) by agroinfiltration.Molecular and functional analysis of monoclonal antibodies in support of biologics development.Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce.Pichia pastoris secretes recombinant proteins less efficiently than Chinese hamster ovary cells but allows higher space-time yields for less complex proteinsImprovement of bread dough quality by Bacillus subtilis SPB1 biosurfactant addition: optimized extraction using response surface methodology.Purification of polyclonal antibodies from Cohn fraction II + III, skim milk, and whey by affinity chromatography using a hexamer peptide ligand.Antibody purification via affinity membrane chromatography method utilizing nucleotide binding site targeting with a small molecule.Evaluation of Escherichia coli proteins that burden nonaffinity-based chromatography as a potential strategy for improved purification performance.Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.Molecular recognition of Fc-specific ligands binding onto the consensus binding site of IgG: insights from molecular simulation.Latex agglutination test based on single-chain Fv recombinant antibody fragment.Agroinfiltration as an Effective and Scalable Strategy of Gene Delivery for Production of Pharmaceutical ProteinsFunctionalization of magnetic nanoparticles with high-binding capacity for affinity separation of therapeutic proteinsSecond Osmotic Virial Coefficients and Aggregation of Monoclonal Antibodies by Static Laser Light Scattering
P2860
Q27691364-729FF0D5-4954-4419-9D8C-05E09577DF1EQ28066997-BC826712-6A0F-4073-A3C4-39826F7726C0Q30319933-47E60885-22FA-41F6-9CC0-1CB788EC98E5Q30838510-3B1DF449-67DD-4E8E-B92F-C980203A17E4Q33883354-2E68025D-9244-4BA9-B38B-796A2B7080C1Q33893033-7692E426-EA12-4654-9476-9D18A51D2CEFQ34053852-1A7C7DF8-0C3D-4D4E-92FC-B69275D905E8Q34652077-F8B2EDDD-B568-47BA-83C7-C4CBAC313987Q36021825-2DD94C70-2824-4F9D-8337-D23382D9BF22Q36150524-C4333EB9-6983-49C6-8068-ADEB841D9E63Q36161917-9F23A778-3D0A-4AA8-BD4F-9C193CCC47ACQ36316926-094261BD-E90E-4D17-B4A0-D7578B02FA87Q36351140-D6CC6C0C-070C-4C23-920B-545DE21081E5Q36888029-8FE506E2-6DE4-468D-A2C0-D96ECF3B2286Q37114305-B2115742-57C5-4FB2-9A37-51D5BE72B350Q37706587-0053DF71-A947-4C7F-B999-D4B6591ED051Q38089263-0F31F42A-7F4F-4AD2-B0C0-53AE6AF2EA5DQ38127392-ADC2BD59-3F2A-403F-B6B2-194F91986E03Q38206275-34BBDA9A-069E-4C24-81D3-503A98F425BAQ38328960-A5DA9703-670B-41A4-86F9-494137EAD129Q38731632-58BC875C-2989-468B-8281-0137E24CD1FFQ38852051-555F06D6-5F07-4F23-BE57-3185F658A145Q38978532-247EFE04-5278-4005-805C-F7FE404FB20AQ39001712-7263676D-342A-4F9E-A810-F6392545F0CFQ39451572-4E75D31C-928C-4D29-9762-3736E0C3C92EQ39647991-1BC9AB04-8C60-476C-ADC8-130A52FB7538Q41986845-B6D3C5BC-4A70-456E-82E2-3D6D1433ABAFQ43575839-007DDD15-06BC-40B6-8980-EE47DB225C73Q44864973-513489F8-B31F-4290-8F17-C205D2080519Q45926628-23B275B9-EA98-4D08-B72A-19810997DEC1Q50512697-A2A2F130-A94C-4F66-A522-FCB8CC69293EQ51044896-783168E4-2804-49E7-B1D7-1021FE5C4CD4Q53512112-39CE3832-1244-4661-8172-C7A5936C8FE0Q54353004-C85E2EC2-5F68-42D8-BE01-2ACDCB78DB2CQ56983558-D8553F98-54DD-46B5-908A-24DE13BBF630Q57988313-329FA257-D224-4B30-B7E9-C0051061CEB3Q58373511-B09FF056-72EF-4667-9BE9-9B09024B2E46
P2860
Antibodies and genetically engineered related molecules: production and purification.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Antibodies and genetically engineered related molecules: production and purification.
@ast
Antibodies and genetically engineered related molecules: production and purification.
@en
type
label
Antibodies and genetically engineered related molecules: production and purification.
@ast
Antibodies and genetically engineered related molecules: production and purification.
@en
prefLabel
Antibodies and genetically engineered related molecules: production and purification.
@ast
Antibodies and genetically engineered related molecules: production and purification.
@en
P50
P356
P1476
Antibodies and genetically engineered related molecules: production and purification
@en
P2093
A Cecília A Roque
M Angela Taipa
P304
P356
10.1021/BP030070K
P577
2004-05-01T00:00:00Z